What is the recommended post‑exposure prophylaxis (PEP) for HIV in adults, including preferred antiretroviral regimen, dosing, baseline investigations, follow‑up schedule, and adjustments for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HIV Post-Exposure Prophylaxis (PEP)

Immediate Action Required

Start PEP within 1 hour if possible, but no later than 72 hours after exposure—do not delay for any test results, source information, or expert consultation. 1, 2

Critical Timing Evidence

  • Primate studies demonstrate 100% protection when PEP starts at 12 or 36 hours post-exposure, but only 67% protection at 72 hours, with complete failure (100% viral rebound) when initiated at day 3. 2
  • Effectiveness declines sharply with each hour of delay. 2
  • If uncertain about the optimal regimen, start with any basic regimen immediately rather than waiting. 2

Indications for PEP

Initiate PEP when all three criteria are met: 1, 2

  1. Timing: Exposure occurred within the past 72 hours 1, 2
  2. Risk: Substantial risk exposure (sexual contact, needlestick, injection drug use, or other exposure to blood/body fluids via nonintact skin or mucous membranes) 1
  3. Source status: Source person is HIV-positive without sustained viral suppression, OR source HIV/viral suppression status is unknown 1, 2

Do NOT initiate PEP if: 1

  • Source is confirmed HIV-negative
  • Source is HIV-positive with documented sustained viral suppression (undetectable viral load)
  • Exposure occurred >72 hours ago (insufficient evidence to support efficacy) 2

Preferred Antiretroviral Regimens (28 Days)

First-Line Options for Adults and Adolescents

Option 1: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as single-tablet regimen 1, 2, 3

Option 2: Dolutegravir + (tenofovir alafenamide OR tenofovir disoproxil fumarate) + (emtricitabine OR lamivudine) 1, 2, 3

These integrase inhibitor-based regimens have replaced older zidovudine-based options and represent the current 2025 CDC standard. 1, 2

Duration

  • Complete the full 28-day course regardless of tolerability issues (modern regimens are far better tolerated than older options). 1, 2
  • Discontinue only if source is later confirmed HIV-negative. 2

Baseline Testing Before First Dose

Do not delay the first PEP dose for any pending laboratory results. 1, 2

Required Baseline Tests

  • HIV testing: Rapid (point-of-care) HIV test OR laboratory-based antigen/antibody combination HIV test 1, 2
  • Add HIV nucleic acid testing (NAT) if the exposed person has received long-acting injectable PrEP in the past (to detect acute infection that may be missed by antibody tests) 2
  • Hepatitis B and C serology 3
  • Pregnancy test for persons of childbearing potential 3
  • Baseline creatinine (for tenofovir-containing regimens) 3

Routine Toxicity Monitoring No Longer Recommended

  • The 2025 guidelines eliminate routine laboratory monitoring for antiretroviral drug toxicity during the 28-day PEP course. 3

Follow-Up Schedule

24-Hour Check-In

  • Remote or in-person visit with medical provider to assess adherence, tolerability, and address questions 1
  • Re-evaluate as additional source information becomes available and adjust regimen if necessary 2

4–6 Weeks Post-Exposure

  • Laboratory HIV antigen/antibody combination test plus diagnostic NAT 1, 2
  • This visit may be deferred if PEP was started within 24 hours and no doses were missed 2

12 Weeks Post-Exposure (Final)

  • Laboratory HIV antigen/antibody combination immunoassay and diagnostic NAT to confirm seronegative status 1, 2
  • This shortened follow-up (from the previous 6-month window) reflects improved test sensitivity 3

Renal Impairment Adjustments

For Tenofovir-Containing Regimens

  • Tenofovir alafenamide (TAF): Preferred over TDF in renal impairment; no dose adjustment needed for eGFR ≥15 mL/min 3
  • Tenofovir disoproxil fumarate (TDF): Requires dose adjustment or alternative regimen if eGFR <60 mL/min 3
  • Dolutegravir: No dose adjustment needed for renal impairment 3
  • Bictegravir: Use with caution if eGFR <30 mL/min 3

Special Populations

Pregnancy and Breastfeeding

  • PEP is safe and recommended during pregnancy and breastfeeding 3, 4
  • Preferred regimens remain the same (integrase inhibitor-based) 3

Sexual Assault Survivors

  • Provide three-drug PEP regardless of assailant characteristics 5
  • Integrate with STI prophylaxis and emergency contraception 1

Persons on PrEP

  • If exposure occurs while on daily oral PrEP with good adherence, PEP may not be necessary—consult expert guidance 1
  • If exposure occurs after recent long-acting injectable PrEP (cabotegravir), use HIV NAT for baseline testing and consider alternative PEP regimens to avoid resistance 1, 2

Transition to PrEP

Inform all PEP recipients that pre-exposure prophylaxis (PrEP) can reduce future HIV risk if ongoing exposure continues. 1

  • Offer PrEP options to persons with ongoing indications 1
  • Create a specific nPEP-to-PrEP transition plan for those who accept 1
  • Daily oral TDF/FTC or long-acting injectable cabotegravir are effective PrEP options 6

Common Pitfalls to Avoid

  • Never delay PEP while awaiting source HIV testing, expert consultation, or optimal regimen selection—start immediately with a basic regimen if needed 2
  • Do not test discarded needles for HIV contamination; this is not recommended and delays care 2
  • Do not initiate PEP for community needlestick injuries (e.g., stepping on a discarded needle in a park) unless there is clear evidence of fresh blood and high-risk source 5
  • Ensure 28-day completion even if side effects occur; modern regimens have excellent tolerability profiles 2
  • Do not use PEP as a substitute for PrEP in persons with repeated high-risk exposures—transition to PrEP instead 1

References

2
Guideline

Timing and Initiation of HIV Post‑Exposure Prophylaxis after Needlestick Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How soon after a needlestick injury should HIV post‑exposure prophylaxis (PEP) be initiated?
After an open‑mouth kiss with a sex worker while I had a non‑bleeding oral ulcer, and a hand‑to‑genital contact without any insertion or exchange of bodily fluids, can I be confident that I have not contracted HIV and that no post‑exposure prophylaxis or further testing is needed?
Can HIV be transmitted through a brief open‑mouth kiss lasting 5–10 seconds in a healthy individual without oral bleeding or lesions?
If a healthcare worker has a negative HIV test performed within 72 hours after a needle‑stick injury with no visible blood, should post‑exposure prophylaxis (PEP) still be initiated?
What are the recommended two‑drug and three‑drug regimens for HIV post‑exposure prophylaxis, including dosing for adults and children?
What are the Navy's limited‑duty patient guidelines, including required clinical evaluation, documentation, specific duty restrictions, treatment protocols, review frequency, and referral criteria for a Medical Evaluation Board?
What is the appropriate treatment for viral labyrinthitis?
When is CA‑125 measurement indicated and how should the results be interpreted?
What are the nursing skills, procedures, and device considerations for transcatheter aortic valve replacement (TAVR), including system relevance, indications, contraindications, baseline assessment, required supplies, pre‑procedure steps, intra‑procedure steps, post‑procedure care, normal parameters, expected physiologic response, alarms/troubleshooting, complications with nursing interventions, red‑flag signs, ongoing reassessment, and documentation?
How should I evaluate and manage flatulence and abdominal distension in an 8-year-old child?
What is the gold‑standard test for diagnosing dengue infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.